發稿單位：
Science Direct
發稿時間：
Received 26 February 2020,
Accepted 27 February 2020,
Available online 4 March 2020.
撰 稿 者：
Philippe Colson
Jean-Marc Rolain
Jean-Christophe Lagier
Philippe Brouqui
Didier Raoult
原文連結：
https://www.sciencedirect.com/science/article/pii/
S0924857920300820?via%3Dihub#!
https://reurl.cc/yZnWpa
_______________________________________________
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
氯喹和羥氯喹可作為有效抵抗武漢肺炎的武器
Repositioning of drugs for use as antiviral treatments is a critical need.
使用既有的貯藏藥品對於作為病毒性的治療是一個急切的需要.
It is commonly very badly perceived by virologists, as we experienced when
reporting the effectiveness of azithromycin for Zika virus.
它通常非常慢的被病毒學家察覺, 像我們經歷過的當時阿奇黴素有效於茲卡病毒的報告.
A response has come from China to the respiratory disease caused by the new
coronavirus (SARS-CoV-2) that emerged in December 2019 in this country.
2019 年 12 月一個來自中國對於呼吸道疾病導致由新的冠狀病毒(SARS-CoV-2)發生在這
個國家.
Indeed, following the very recent publication of results showing the in vitro
activity of chloroquine against SARS-CoV-2, data have been reported on the
efficacy of this drug in patients with SARS-CoV-2-related pneumonia (named
COVID-19) at different levels of severity.
更確切的說, 緊接而來的最近發表的結果顯示氯喹的實驗性預防 SARS-CoV-2, 資料已經
報告出在藥品對於患有 SARS-CoV-2 病人有關肺炎(名為武漢肺炎)在嚴重的不同程度等級
的效力.
Thus, following the in vitro results, 20 clinical studies were launched in
several Chinese hospitals.
如此, 緊接著在幾個中國的醫院 20 個臨床研究下已經投入實驗性的結果.
The first results obtained from more than 100 patients showed the superiority
of chloroquine compared with treatment of the control group in terms of
reduction of exacerbation of pneumonia, duration of symptoms and delay of
viral clearance, all in the absence of severe side effects.
第一個結果從超過 100 個病人顯露出氯喹與肺炎惡化設法減少期限的控制群治療法的比
較下是有優勢的, 在持續的症狀與病毒清除的延遲上, 全部都沒有嚴重的副作用.
This has led in China to include chloroquine in the recommendations regarding
the prevention and treatment of COVID-19 pneumonia.
這在中國引進包括氯喹在關於預防和武漢肺炎的治療上具有優勢.
There is a strong rationality for the use of chloroquine to treat infections
with intracellular micro-organisms.
這裡有一個強烈的理由在對於氯喹的使用上去治療有關於細胞內微生物的傳染病.
Thus, malaria has been treated for several decades with this molecule.
如此, 該分子用於瘧疾治療已有數十年.
In addition, our team has used hydroxychloroquine for the first time for
intracellular bacterial infections since 30 years to treat the intracellular
bacterium Coxiella burnetii, the agent of Q fever, for which we have shown in
vitro and then in patients that this compound is the only one efficient for
killing these intracellular pathogens.
此外, 我們的團隊已使用羥氯喹在第一次在細胞內細菌性的感染從 30 年前去治療細胞內
細菌貝氏考克斯菌, Q 型流感試劑, 為此我們展示了實驗性和及時在病人上使用化合物是
唯一有效去殺除這些細胞外的病原體.
Since then, we have also shown the activity of hydroxychloroquine on
Tropheryma whipplei, the agent of Whipple's disease, which is another
intracellular bacterium for which hydroxychloroquine has become a reference
drug.
自此, 我們也展示了在 Tropheryma whipplei 上羥氯喹的活動力, Whipple's disease
的試劑是另一個細胞內的細菌為此羥氯喹可成為一個參考的藥物.
Altogether, one of us (DR) has treated ~4000 cases of C. burnetii or T.
whipplei infections over 30 years (personal data).
總之, 在我們(醫師)之中治療到約 4000 案貝氏考克斯菌或 Tropheryma whipple 的感染
者超過 30 年(個人資料).
Regarding viruses, for reasons probably partly identical involving
alkalinisation by chloroquine of the phagolysosome, several studies have
shown the effectiveness of this molecule, including against coronaviruses
among which is the severe acute respiratory syndrome (SARS)-associated
coronavirus.
關於病毒, 有理由由吞解體的氯喹大概部分完全相同的需要鹼化(這裡可能要醫學常識的
人來翻), 多項研究顯示這個分子的效力, 包括對抗冠狀病毒裡是在這之中的非常嚴重急
性呼吸道併發症(SARS)-與之同類型冠狀病毒.
We previously emphasised interest in chloroquine for the treatment of viral
infections in this journal, predicting its use in viral infections lacking
drugs.
我們在期刊上事先強調在氯喹用於病毒感染治療上的重要性, 預料它為使用在病毒感染上
所欠缺的藥品(lacking drugs?不太會翻).
Following the discovery in China of the in vitro activity of chloroquine
against SARS-CoV-2, discovered during culture tests on Vero E6 cells with 50%
and 90% effective concentrations (EC50 and EC90 values) of 1.13 μM and 6.90
μM, respectively (antiviral activity being observed when addition of this
drug was carried out before or after viral infection of the cells), we
awaited with great interest the clinical data.
緊接著在中國發現實驗性氯喹對於對抗 SARS-CoV-2 的活動, 發現在培養測試 Vero E6
細胞於 1.13 uM 有效濃度 50 % 和 6.90 uM 有效濃度 90% (EC50 和 EC90 值)期間, 分
別地(抗病毒物質活動被觀測到當添加這個藥品時是可以在這細胞受病毒感染之前或之後
可被實現作用的), 我們期待對於臨床有更重要價值的資料.
The subsequent in vivo data were communicated following the first results of
clinical trials by Chinese teams [4] and also aroused great enthusiasm among
us.
緊接而來在活的有機體內的資料是傳染隨著由中國團隊臨床試驗的第一個結果且也喚起在
我們之中的重大的熱忱.
They showed that chloroquine could reduce the length of hospital stay and
improve the evolution of COVID-19 pneumonia [4,6], leading to recommend the
administration of 500 mg of chloroquine twice a day in patients with mild,
moderate and severe forms of COVID-19 pneumonia.
他們顯示氯喹可降低在醫院停留時間且改善感染武漢肺炎發展, 主要地來說建議溫和適中
和嚴重武漢肺炎症狀的病人使用氯喹 500 mg 一天兩次.
At such a dosage, a therapeutic concentration of chloroquine might be reached.
在這樣的劑量, 一個氯喹的濃度治療可能可以達到效果.
With our experience on 2000 dosages of hydroxychloroquine during the past 5
years in patients with long-term treatment (>1 year), we know that with a
dosage of 600 mg/day we reach a concentration of 1 μg/mL.
在我們經驗中在過去 5 年中 2000次羥氯喹的劑量用在病人上隨著長時間的治療(大於 1
年), 我們知道在每天 600 mg的一個劑量我們可達到在 1 ug/mL 的濃度下.
The optimal dosage for SARS-CoV-2 is an issue that will need to be assessed
in the coming days.
對於 SARS-CoV-2 最理想的劑量那將會是需要在未來的日子裡確定的一個論點.
For us, the activity of hydroxychloroquine on viruses is probably the same as
that of chloroquine since the mechanism of action of these two molecules is
identical, and we are used to prescribe for long periods hydroxychloroquine,
which would be therefore our first choice in the treatment of SARS-CoV-2.
對我們而言, 羥氯喹在病毒上的活動力是可能同樣於氯喹而從這兩個分子的功能結構是來
看是同樣的, 且我們使用羥氯喹於處方已有很長時間, 因此我們在 SARS-CoV-2 的治療上
使用羥氯喹是第一選擇.
For optimal treatment, it may be necessary to administer a loading dose
followed by a maintenance dose.
對於最理想的治療而言, 它可能必須要給予一個超負荷的劑量緊接著維持一個劑量.
___________________________________________________________
以上翻譯有錯請指證,
因為我不是讀醫的,
對於一些名詞我不是很了解,
有的是從網路上查的.
另外目前中國是用磷酸氯喹在治療,
國外有人用硫酸羥氯喹在治療,
差別在於硫酸羥氯喹比磷酸氯喹便宜,
它是用在治療關節問題上的.
但它不是疫苗,
它只是大幅減緩武漢肺炎的症狀,
可以讓你保命到疫苗研發出來為止.
至於服用的方式,
請跟醫師和藥劑師商量,
不要自己亂用.
__________________________________________
這個網址是比較完整的報告,
https://docs.google.com/document/d/e/
2PACX-1vTi-g18ftNZUMRAj2SwRPodtscFio7bJ7GdNgbJAGbdfF67WuR
JB3ZsidgpidB2eocFHAVjIL-7deJ7/pub?fbclid=IwAR3HXmAaRvsKQw
tD4mT0W6NU4bTJvZnR6f3KLRcsWkXSOGn33dbdR1KyS0Q
https://reurl.cc/MvZWKK
__________________________________________
伊隆·馬斯克 Elon Musk推薦的, 網址點進去就是上面這個報告,
https://imgur.com/a/qw6qx7X